Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria

BackgroundDronedarone is approved by the U.S. Food and Drug Administration for the treatment of patients with atrial fibrillation (AF) as a safe alternative to amiodarone. There are no full-length published reports describing the effectiveness of acute dronedarone use against AF in experimental or clinical studies.ObjectiveThe purpose of this study was to determine the effect of acute dronedarone and amiodarone on electrophysiological parameters, and their anti-AF efficacy in canine isolated arterially perfused right atria.MethodsTransmembrane action potentials and pseudoelectrocardiograms were recorded. Acetylcholine (ACh, 1.0 μM) was used to induce persistent AF.ResultsAmiodarone-induced changes were much more pronounced than those of dronedarone on (1) action potential duration (ΔAPD90, +51 ± 17 ms vs. 4 ± 6 ms, P >.01), (2) effective refractory period (ΔERP, +84 ± 23 ms vs. 18 ± 9 ms, P <.001), (3) diastolic threshold of excitation (ΔDTE, +0.32 ± 0.11 mA vs. 0.03 ± 0.02 mA, P <.001), and (4) Vmax (ΔVmax, −43 ± 14% vs. −11 ± 4%, P <.01, n = 5 to 6; all recorded at 10 μM, cycle length = 500 ms). Persistent AF was induced in 10 of 10 atria exposed to ACh alone; subsequent addition of dronedarone or amiodarone terminated AF in 1 of 7 and 4 of 5 atria, respectively. Persistent ACh-mediated AF was induced in 5 of 6 and 0 of 5 atria pretreated with dronedarone and amiodarone, respectively.ConclusionThe electrophysiological effects and anti-AF efficacy of acute dronedarone are much weaker than those of amiodarone in a canine model of AF. The efficacy of acute dronedarone to prevent induction of acetylcholine-mediated AF as well as to terminate persistent AF in canine right atria is relatively poor. Our data suggest that acute dronedarone is a poor substitute for amiodarone for acute cardioversion of AF or prevention of AF recurrence.